The purpose of this study is to provide expanded access to lumasiran for adults andpediatric patients with Primary Hyperoxaluria Type 1 (PH1),
Choosing to participate in an expanded access program is an important personal decision.
Talk with your doctor and family members or friends about deciding to join a research
study. To learn more about this study, please have your doctor contact the study research
staff using the Contacts provided. For general information, see the link provided in More
Information.
Drug: Lumasiran
Lumasiran administered as a subcutaneous (SC) injection
Other Name: ALN-GO1
Inclusion Criteria:
- Documented diagnosis of Primary Hyperoxaluria Type 1
Exclusion Criteria:
- Clinically significant health concerns (with the exception of PH1)
- Received an investigational agent within 30 days before the first dose of lumasiran
or are in follow-up of another clinical study
- Previously or currently participating in lumasiran clinical study
- History of liver transplant
Medical Director, Study Director
Alnylam Pharmaceuticals